Gufic Biosciences Past Earnings Performance
Past criteria checks 2/6
Gufic Biosciences has been growing earnings at an average annual rate of 23.5%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 16.6% per year. Gufic Biosciences's return on equity is 14.8%, and it has net margins of 10.6%.
Key information
23.5%
Earnings growth rate
20.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 16.6% |
| Return on equity | 14.8% |
| Net Margin | 10.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
There's Reason For Concern Over Gufic Biosciences Limited's (NSE:GUFICBIO) Massive 26% Price Jump
Nov 07
We Think You Should Be Aware Of Some Concerning Factors In Gufic Biosciences' (NSE:GUFICBIO) Earnings
Jun 06Is Gufic Biosciences (NSE:GUFICBIO) Using Too Much Debt?
Jun 17These 4 Measures Indicate That Gufic Biosciences (NSE:GUFICBIO) Is Using Debt Reasonably Well
Sep 02Should You Be Adding Gufic Biosciences (NSE:GUFICBIO) To Your Watchlist Today?
May 07Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock
Dec 07This Is The Reason Why We Think Gufic Biosciences Limited's (NSE:GUFICBIO) CEO Might Be Underpaid
Sep 15Is Now The Time To Put Gufic Biosciences (NSE:GUFICBIO) On Your Watchlist?
Aug 12Gufic Biosciences' (NSE:GUFICBIO) Performance Is Even Better Than Its Earnings Suggest
Jun 11If You Like EPS Growth Then Check Out Gufic Biosciences (NSE:GUFICBIO) Before It's Too Late
Mar 19What Percentage Of Gufic Biosciences Limited (NSE:GUFICBIO) Shares Do Insiders Own?
Mar 01Gufic Biosciences (NSE:GUFICBIO) Has A Pretty Healthy Balance Sheet
Feb 11Is Gufic Biosciences' (NSE:GUFICBIO) 164% Share Price Increase Well Justified?
Jan 23
Why Gufic Biosciences Limited (NSE:GUFICBIO) Looks Like A Quality Company
Jan 05Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock
Dec 18Here's What Gufic Biosciences Limited's (NSE:GUFICBIO) Shareholder Ownership Structure Looks Like
Dec 01Gufic Biosciences (NSE:GUFICBIO) Has A Somewhat Strained Balance Sheet
Nov 13The Gufic Biosciences (NSE:GUFICBIO) Share Price Has Gained 116%, So Why Not Pay It Some Attention?
Oct 19Can Gufic Biosciences Limited's (NSE:GUFICBIO) ROE Continue To Surpass The Industry Average?
Sep 14I Built A List Of Growing Companies And Gufic Biosciences (NSE:GUFICBIO) Made The Cut
Aug 24Investors Appear Satisfied With Gufic Biosciences Limited's (NSE:GUFICBIO) Prospects
Aug 03Earnings Tell The Story For Gufic Biosciences Limited (NSE:GUFICBIO)
Jul 09Revenue & Expenses Breakdown
How Gufic Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 8,038 | 849 | 1,206 | 0 |
| 30 Jun 24 | 8,145 | 864 | 1,153 | 0 |
| 31 Mar 24 | 8,067 | 861 | 1,132 | 0 |
| 31 Dec 23 | 7,847 | 842 | 1,092 | 0 |
| 30 Sep 23 | 7,604 | 823 | 1,026 | 0 |
| 30 Jun 23 | 7,204 | 793 | 960 | 0 |
| 31 Mar 23 | 6,906 | 797 | 940 | 0 |
| 31 Dec 22 | 6,798 | 819 | 922 | 0 |
| 30 Sep 22 | 6,744 | 826 | 896 | 0 |
| 30 Jun 22 | 6,937 | 857 | 896 | 0 |
| 31 Mar 22 | 7,792 | 958 | 913 | 0 |
| 31 Dec 21 | 7,489 | 884 | 865 | 0 |
| 30 Sep 21 | 7,434 | 829 | 853 | 0 |
| 30 Jun 21 | 6,777 | 769 | 782 | 0 |
| 31 Mar 21 | 4,877 | 442 | 691 | 0 |
| 31 Dec 20 | 4,005 | 305 | 588 | 0 |
| 30 Sep 20 | 3,538 | 243 | 557 | 0 |
| 30 Jun 20 | 3,195 | 123 | 499 | 0 |
| 31 Mar 20 | 3,788 | 227 | 637 | 0 |
| 31 Dec 19 | 3,681 | 243 | 578 | 0 |
| 30 Sep 19 | 3,580 | 232 | 574 | 0 |
| 30 Jun 19 | 3,640 | 249 | 479 | 0 |
| 31 Mar 19 | 3,508 | 219 | 525 | 0 |
| 31 Dec 18 | 3,334 | 164 | 527 | 0 |
| 30 Sep 18 | 3,353 | 168 | 520 | 0 |
| 30 Jun 18 | 3,192 | 164 | 611 | 0 |
| 31 Mar 18 | 3,056 | 165 | 479 | 0 |
| 31 Dec 17 | 2,887 | 181 | 492 | 0 |
| 30 Sep 17 | 2,651 | 154 | 455 | 0 |
| 30 Jun 17 | 2,544 | 124 | 432 | 0 |
| 31 Mar 17 | 2,455 | 90 | 427 | 0 |
| 31 Dec 16 | 2,419 | 105 | 402 | 0 |
| 30 Sep 16 | 2,329 | 98 | 379 | 0 |
| 30 Jun 16 | 2,201 | 88 | 345 | 0 |
| 31 Mar 16 | 2,022 | 73 | 332 | 0 |
| 31 Dec 15 | 1,806 | 62 | 535 | 0 |
| 30 Sep 15 | 1,588 | 45 | 497 | 0 |
| 30 Jun 15 | 1,500 | 36 | 231 | 0 |
| 31 Mar 15 | 1,516 | 42 | 212 | 0 |
| 31 Dec 14 | 1,533 | 43 | 385 | 0 |
| 30 Sep 14 | 1,503 | 47 | 382 | 0 |
| 30 Jun 14 | 1,366 | 47 | 142 | 0 |
| 31 Mar 14 | 1,230 | 43 | 339 | 0 |
| 31 Dec 13 | 1,104 | 37 | 335 | 0 |
Quality Earnings: GUFICBIO has high quality earnings.
Growing Profit Margin: GUFICBIO's current net profit margins (10.6%) are lower than last year (10.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GUFICBIO's earnings have grown significantly by 23.5% per year over the past 5 years.
Accelerating Growth: GUFICBIO's earnings growth over the past year (3.2%) is below its 5-year average (23.5% per year).
Earnings vs Industry: GUFICBIO earnings growth over the past year (3.2%) did not outperform the Pharmaceuticals industry 20.4%.
Return on Equity
High ROE: GUFICBIO's Return on Equity (14.8%) is considered low.